Caplin Point Laboratories (524742) investor relations material

Executive summary

• Revenue grew by up to 20.7% year-over-year in Q1 FY27, with strong contributions from both conventional/emerging and U.S. markets.

• Profit after tax for Q1 FY27 was ₹179 Crores, up 18.8% year-over-year, with robust EBITDA and PAT growth.

• Expansion continues in Latin America, U.S., and new regulated markets, supported by investments in manufacturing, R&D, automation, and digitalization.

• No external debt has been taken for expansion; all investments and capex are funded through internal accruals, maintaining a strong balance sheet.

• Board recommended a final dividend of ₹4 per share for FY26, subject to AGM approval.

Financial highlights

• Q1 FY27 revenue reached ₹644 Crores, up 20.7% year-over-year; U.S. market revenue grew 26% to ₹137 Crores.

• Q1 FY27 EBITDA was ₹247 Crores, up 23% year-over-year; EBITDA margin at 38.4%.

• Gross margin for Q1 FY27 was 59.8%; PAT margin was 27.8%.

• Free cash reserves stood at ₹1,502 Crores; total liquid assets at ₹2,875 Crores as of June 30, 2026.

• Basic EPS rose 15.8% year-over-year to ₹23.27.

Outlook and guidance

• Company expects continued growth in Latin America and U.S. markets, with new product launches and capacity expansions planned.

• Capex budget of over ₹1,000 Crores, with 50% nearing completion and the rest to be incurred over 2-3 years, all funded by internal accruals.

• Focus on sustainable long-term growth through expansion in regulated markets and backward integration.

• Plans to launch 12 new products in the U.S. in FY27 and expand into Canada, Australia, Mexico, and Brazil.

• Anticipated increase in business once new factories are operational in 1–2.5 years.